MO) at a ratio of 1 mg protein per 1 ml swollen gel. B cells (40 ml at 106 cells/ml) were added to a 75 cm 2 flask (Falcon Labware, Oxnard, CA) with 80 ttl of packed beads (2/sg protein per milliliter final concentration) and incubated for 24-48 h. Cells and beads were then removed and centrifuged; the pellet was resuspended in RPMI-1640, layered over Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway, N J), and centrifuged for 10 min at 400 g. The cells were collected from the interface and washed twice. In some experiments, anti-Ig blasts and/or B cells were fractionated on Percoll (Sigma Chemical Co.) density gradients. Anti-Ig blasts were essentially all found in the light-density fractions (<I.065 g/ml), while >75% of splenic B cells were of density >1.080 g/m].
Blasts were also prepared by culture of B cells with either dextran sulfate (DxS) (50 #g/ml) or 8-mercaptoguanosine (8-MG) (0.5 mM). After 24 or 48 h, cells were washed and recultured in microtiter wells.
T Cell Supernatants. Lymphokine-containing supernatant (SN) was obtained from EL-4 cells as previously described, except serum-free conditions were used (6) . This preparation contains substantial BCDF3,/BSF-1 activity, as assayed on LPS-treated B cells (3) and with anti-Ig-induced B cell proliferation (7) . For the experiment shown in Table  IV , EL-4 SN was passed over a Con A-agarose column. Material that induced proliferation of anti-Ig blasts was found in the flow-through, while BSF-1 was retained and eluted with 0.4 M a-methyl mannoside.
Cell Culture. Splenic B cells were prepared by treatment with monoclonal anti-Thy 1 (kindly provided by Dr. E. S. Vitetta) and baby rabbit complement (Pel-Freeze Biologicals, Rogers, AR). B cells and blasts were cultured in 96-well flat-bottomed plates (4 × 104 cells in 200 ~1 RPMI-1640 supplemented with 5% FCS [Gibco Laboratories, Grand Island, NY] and 50 uM 2-ME) for 5 d at 37°C in a humidified atmosphere with 10% CO2.
Radioimmunoassay. Culture supernatant was assayed for Ig isotypes by a solid-phase RIA. Polyvinyl chloride plates (Falcon Labware) were coated with an antibody (goat antiIgM + IgG), which recognized all tested isotypes. After incubation with sample, the plate was washed and incubated with ~25I-labeled isotype-specific antibody. The concentration of Ig was determined by comparison to standard curves of myeloma Ig with a microcomputer program (kindly provided by L. Simpson). The isotype-specific antibodies had negligible (<0.1%) crossreactivity with inappropriate heavy chain isotypes or with light chains.
Proliferation Assay. Anti-Ig blasts were cultured as above for 48 h, then pulsed with
[3H]thymidine (1 uCi/well). After 16 h, wells were harvested onto glass fiber filters and radioactivity was assessed by liquid scintillation counting.
Results
Lymphokine Stimulation of lgG Secretion from Anti-Ig Blasts. Splenic B cells were cultured for 48 h with anti-Ig-coated Sepharose beads; after removal of the beads, culture of these blasts with EL-4 SN resulted in a striking increase in the amount of IgG1 secreted into the medium. The pattern of IgG isotypes secreted by normal B cells and anti-Ig blasts stimulated with lymphokines in EL-4 SN alone is shown in Table I . EL-4 SN induced low levels of all IgG isotypes from normal B cells, whereas anti-Ig blasts cultured with EL-4 SN secreted predominantly IgG1 (Table I) . Similar results were obtained with B cell blasts prepared with anti-Ig or anti-# (Table I) , and with anti-Ig blasts separated on Percoll density gradients (data not shown). The magnitude of the IgG1 response from anti-Ig blasts was markedly higher than that observed with B cells. In six separate experiments, anti-Ig blasts secreted an average of 3.9 ug/ml IgG1 in response to EL-4 SN, vs. 0.3 ug/ml from splenic B cells. The IgG isotype profile of B cells and anti-Ig blasts cultured with LPS is also shown in Table I . Both cell types yielded similar results: substantial IgG3 secretion, less IgG1, and still lower amounts of IgG2a and IgG2b (Table I) . Anti-lg blasts were cultured for 2 d, then assayed for incorporation of [3H]thymidine. * EL-4 SN was passed over a Con A-agarose colunm and eluted as described in Materials and Methods; a dilution giving half-maximal BSF-I activity was added. (Table  III) . The same wells were also assayed for polyclonal IgM secretion induced by EL-4 SN; anti-BSF-1 had little or no effect on this response, indicating that the inhibition of IgG1 secretion was isotype specific. Proliferative Responses of Anti-lg Blasts. It was possible that anti-lg blasts prepared here proliferated in response to BSF-1, in contrast to previous results (11, 15). This was exanfined by determining the effect of anti-BSF-1 on proliferation in response to EL-4 SN, and by testing a partially purified preparation of BSF-1 on anti-Ig blasts (Table IV) Table IV , the eluate from a Con Aagarose column had little mitogenic activity on anti-Ig blasts; this same fraction had substantial BSF-1 activity in a costimulator assay (7), but did not induce IgG secretion from anti-Ig blasts (data not shown).
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determined optimal concentrations of antibody required to neutralize BCDF? activity on LPS-treated B cells (data not shown). When anti-BSF-1 was included in cultures of anti-Ig blasts, the IgG1 response to EL-4 SN was suppressed
Discussion
The T cell-derived lymphokine BSF-1 increases the number of resting B cells that enter S in response to anti-Ig (7, 16) . Anti-Ig-pretreated cells are not sensitive to BSF-1 (17), suggesting that BSF-1 acts primarily during early stages of entry into cell cycle. In contrast, studies (5) with BCDF'y, which is apparently identical to BSF-1, showed that it was most effective with previously activated cells. Two important points can be made based on experiments reported here. First, B cells treated with anti-Ig secrete high levels of IgG1 in response to lymphokines present in EL-4 SN. Second, anti-Ig blasts appear to be capable of responding to a lymphokine with the antigenic properties of BSF-1. The latter conclusion is based on the ability of anti-BSF-1 to specifically inhibit IgG1 secretion, and provides strong evidence that anti-Ig blasts are responsive to BSF-1. Thus, treatment with anti-Ig may render B cells insensitive to one effect of BSF-1 (proliferation enhancement) but not another (isotype switching).
The experiment shown in Table IV suggests that BSF-1 alone is incapable of either maintaining proliferation of anti-Ig blasts or inducing IgG1 secretion. Thus, another lymphokine capable of maintaining B cell proliferation and inducing Ig secretion appears to act in concert with BSF-1 on anti-Ig blasts. It should be noted that complete inhibition of IgG1 secretion was not always obtained with anti-BSF-1 (cf. Exp. 2, Table III) . A definitive explanation for this finding will require the use of purified lymphokines. The finding that B cell blasts produced by 8-MG or DxS do not show heightened IgG1 responses (Table  II) could reflect low responsiveness to either BSF-1 or to another lymphokine.
In conclusion, anti-Ig blasts can be induced to switch isotypes by T cell-derived lymphokines alone. Since anti-Ig blasts do not divide or secrete Ig in the absence of further stimulation, they may provide a useful model for elucidating signals for growth and for stimulation of IgM vs. IgG secretion.
Summary
We have determined whether B cells previously activated by anti-Ig (anti-Ig blasts) are responsive to lymphokines that induce isotype switching. Culture of anti-Ig blasts with a mixture of lymphokines, including BSF-1, resulted in marked secretion of IgM and IgG1, but not other IgG isotypes. The IgG1 response of anti-Ig blasts to lymphokines was 13-fold greater than was observed with splenic B cells. B cell blasts induced by 8-mercaptoguanosine or dextran sulfate did not secrete high levels of any IgG isotype in response to lymphokines alone. An mAb against BSF-1 suppressed the IgG1 response of anti-Ig blasts, but not the IgM response to lymphokines. These data suggest that anti-Ig-treated B cells respond to at least one of the effects of BSF-1.
